B+L report finds resistance of some ocular pathogens has increased in U.S.

Article

During the ARVO meeting last week, Bausch + Lomb researchers presented results from the 5th Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study in the United States, as well as the first data from the study in Canada.

Orlando, FL-During the ARVO meeting last week, Bausch + Lomb researchers presented results from the 5th Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study in the United States, as well as the first data from the study in Canada. 

For the U.S. study, participants from 27 sites collected 239 isolates of Streptococcus pneumoniae, Staphylococcus aureus, coagulase-negative staphylococci (CoNS), Pseudomonas aeruginosa, and Haemophilus influenzae, all organisms frequently implicated in bacterial infections of the eye, and tested them for susceptibility to as many as 16 available ophthalmic antibiotics. From 2012 to 2013, the report found that antibiotic resistance rates increased among the isolates of staphylococci and P. aeruginosa. Preliminary results show non-susceptibility of P. aeruginosa to the antibiotics ciprofloxacin and imipenem may have doubled from 2012 to 14% and 21%.

"The ARMOR study provides susceptibility information that may be useful in antibiotic selection and ocular infection management while keeping the issue of evolving antibiotic resistance itself top-of-mind for the eye care professional.  Because ineffective antibiotic therapy may not only be sight-threatening but also hastens the development of treatment resistant strains of bacteria, we all bear some responsibility for continued vigilance regarding resistance patterns and care in therapeutic selection,” said Mitchell A. Jackson, MD, Founder and Medical Director of Jacksoneye, Lake Villa, IL.

Recent Videos
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Bonnie An Henderson in an interview for the EnVision Summit
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
© 2024 MJH Life Sciences

All rights reserved.